Seres, AZ partner on microbiome research to treat cancer, predict response

Seres gained $1.27 (25%) to $6.38 on Monday after it announced a three-year partnership with AstraZeneca to evaluate microbiome-based approaches to improve and predict patient response to immunotherapies.

Seres Therapeutics Inc. (NASDAQ:MCRB) will receive $20 million over two years, and will be reimbursed by AstraZeneca plc (LSE:AZN; NYSE:AZN) for research expenses. AZ obtained an option to negotiate for rights to programs and other inventions that arise from the collaboration...